SA
REGN icon

Sovran Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Sovran Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$359K Sell
516
-5,503
-91% -$3.75M 0.03% 439
2026
Q1 		$4.26M Sell
6,019
-2,600
-30% -$1.99M 0.33% 84
2025
Q4 		$6.39M Sell
8,619
-2,519
-23% -$1.71M 0.54% 48
2025
Q3 		$7.28M Buy
11,138
+6,118
+122% +$3.46M 0.64% 38
2025
Q2 		$2.75M Buy
+5,020
New +$2.8M 0.29% 97

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sovran Advisors's REGN Position: Q2 2026 in Review

Sovran Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 91% in Q2 2026, selling an estimated $3.75M and leaving 516 shares worth $359K. The position accounts for 0.03% of the portfolio, ranked #439.

Sovran Advisors first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $7.28M in Q3 2025. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Sovran Advisors held 516 shares of Regeneron Pharmaceuticals worth $359K as of Q2 2026.
  • Sovran Advisors sold 5,503 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.75M.
  • Regeneron Pharmaceuticals made up 0.03% of Sovran Advisors's portfolio in Q2 2026, its #439 holding.
  • Sovran Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • Sovran Advisors's Regeneron Pharmaceuticals position peaked at $7.28M in Q3 2025.
  • 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.